[ad_1]
- Bugworks – a US, India and Australia based start-up with globally recognized expertise in drug discovery, has set up a dedicated Immuno-oncology ex vivo research lab at the Bengaluru-based hospital, Cytecare.
- The lab bridges the translation from discovery to development, addressing several hard-to-treat cancers such as gastric, colorectal, renal cell, breast, head and neck, non-small cell lung cancers.
- This partnership between leading drug discovery start-up and leading cancer hospital paves way for the development of novel Immuno-oncology drugs that can be effective in wider patient populations.
- The outcome of this translational research will guide the first-in-human trials, expected to commence in early 2024.
BENGALURU, India, Sept. 19, 2022 /PRNewswire/ — Bugworks Research Inc., a clinical stage biopharmaceutical company, and Cytecare Cancer Hospitals today announced the launch of a first-of-its-kind collaboration. Bugworks develops best-in-class, novel therapies for cancer and infectious diseases & has set up a dedicated research center within Cytecare, which is committed to excellence in treating cancer patients.
The coming together of a leading innovator…
Full story available on Benzinga.com
[ad_2]
Source link
